WO2006025598A1 - 長時間虚血による脳梗塞の抑制剤 - Google Patents
長時間虚血による脳梗塞の抑制剤 Download PDFInfo
- Publication number
- WO2006025598A1 WO2006025598A1 PCT/JP2005/016463 JP2005016463W WO2006025598A1 WO 2006025598 A1 WO2006025598 A1 WO 2006025598A1 JP 2005016463 W JP2005016463 W JP 2005016463W WO 2006025598 A1 WO2006025598 A1 WO 2006025598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ischemia
- cerebral infarction
- administered
- reperfusion
- histidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a drug for suppressing cerebral infarction caused by prolonged cerebral ischemia.
- Cerebral infarction means that blood flow in the brain is insufficient due to blood clots that are formed in blood vessels other than the brain being transported to the brain or cerebrovascular is blocked or thinned due to arteriosclerosis in the cerebral blood vessels. This refers to a disease in which a damaged tissue falls into necrosis. Once a cerebral infarction has occurred, the necrotic brain tissue is not restored, and even if life is saved, dementia symptoms often remain as well as movement paralysis, sensory disturbance, and language impairment. On the other hand, in recent years, lifestyle-related diseases such as hypertension, heart disease, hyperlipidemia, and diabetes have increased, and the risk of cerebral infarction has increased. Therefore, an effective means for treating cerebral infarction is eagerly desired.
- thrombolytic agents are used to dissolve blood clots that cause cerebral infarction and to resume blood flow.
- free radical damage caused by resumption of blood flow is also deeply involved in the pathology of cerebral infarction, and thrombolytic agents alone are not the fundamental solution to necrosis of brain tissue.
- edaravone a free radical force venger for protecting brain tissue from free radicals that cause brain tissue damage
- the drug has side effects such as liver dysfunction and renal dysfunction.
- the data indicate that abnormal fluctuations in clinical laboratory values, such as abnormal liver function values, are as high as 21.4% of patients treated. There is also. There is a problem with the high incidence of side effects, even though it is a treatment for cerebral infarction, which is a fatal disease.
- hypothermia As an alternative to drugs. However, it takes to implement In addition to high costs, there are infections and bleeding tendency due to decreased immunity, so general implementation is difficult.
- a programmed death (apoptosis) of a neuron is caused by a short ischemia (transient ischemia) even if the necrosis (necrosis) of a brain cell is not reached.
- transient ischemia transient ischemia
- Toshiki Kawamoto et al. “Month 1 ⁇ 4: Effect of L-nistidine (singlet oxygen scavenger) during transient forebrain ischemia in rats”, Moon 3 ⁇ 4 Ne Kyoku, No. 4 9-7, No. 6 1 2-6
- page 1 (1 9 9 7) when 5 minutes or 10 minutes of transient forebrain ischemia was loaded, the loss of pyramidal neurons in the hippocampal CA-1 region occurred after 1 week.
- the method of suppressing neuronal cell death in transient ischemia is not always applicable to actual cerebral infarction.
- the cause of cell death due to ischemia is complex, as the mechanism of inhibition of neuronal cell death differs depending on whether the drug is administered before or after ischemia. It depends.
- brain tissue necrosis the direct cause of actual cerebral infarction (brain tissue necrosis) is cerebral ischemia that lasts several hours, and the mechanism of delayed neuronal death that occurs 7 days after several to ten minutes of ischemia Is different.
- transient ischemia causes apoptosis only in neurons, but long-term ischemia necrosis occurs not only in neurons but also in the entire brain tissue including glial cells and vascular endothelial cells.
- the problem to be solved by the present invention is to provide a cerebral infarction inhibitor that is effective for brain tissue necrosis after ischemia for a long time corresponding to actual cerebral infarction and has few side effects. .
- the present inventors have made various studies on drugs capable of suppressing brain tissue necrosis after ischemia for several hours, and found that administration of histidine after reperfusion is extremely effective. As a result, the present invention has been completed.
- the cerebral infarction inhibitor according to the present invention suppresses cerebral infarction due to prolonged ischemia, and is characterized by containing histidine.
- the use according to the present invention is characterized in that histidine is used for producing a therapeutic agent for cerebral infarction due to prolonged ischemia.
- the method for treating cerebral infarction treats cerebral infarction due to prolonged ischemia and is characterized by administering histidine.
- Fig. 1 is a photograph showing the effect of inhibiting cerebral infarction when histidine is administered after prolonged ischemia.
- the cerebral infarction inhibitor of the present invention contains histidine as an active ingredient. Since this histidine is one of the essential amino acids, it is considered that there are few side effects, and large doses are possible. In addition, histidine easily crosses the blood brain barrier and is converted to histamine by decarboxylase in the brain. This histamine is thought to act on brain tissue.
- Cerebral infarction is generally caused by ischemia due to cerebral thrombosis or cerebral embolism, and is accompanied by a morphological disorder (necrosis) of a size that is visible to the naked eye.
- Apoptosis due to ischemia for a very short time for example, several minutes to several tens of minutes
- cerebral blood flow or small thrombus, etc. after several days, only nerve cells that are vulnerable to ischemia fall off. Even if symptoms occur due to this apoptosis, it is much less severe than cerebral infarction and does not endanger life.
- the necrosis and apoptosis mechanisms are clearly different. Therefore, the cerebral infarction inhibitor of the present invention targets cerebral infarction due to prolonged ischemia.
- the “long time” in long-term ischemia is not particularly limited, but means at least a time to the extent that ischemia directly causes necrosis of brain tissue.
- the specific time depends on the cause and extent of ischemia, individual differences, etc., but takes into account the time from the occurrence of ischemia until actual treatment is performed, for example, 1 hour or more, and further 1.5. More than 2 hours, especially more than 2 hours.
- the dosage form and administration form of the inhibitor of the present invention are not particularly limited, but it is preferably administered intravenously as an injection in consideration of the urgency against cerebral ischemia.
- physiological saline adjusted with pH, pure water, distilled water, sterilized water, or the like can be used as the solvent.
- the administration method of histidine in the present invention is larger than the dose of general drugs. As shown in the examples described below, when histidine of 2 0, 5 0 0, 10 0 O mg / kg was administered twice to a rat weighing approximately 300 g, dose-dependent cerebral infarction Suppression The control effect was obtained. Considering these results, the dose for humans can be 50 to 50 O mg Z kg per dose. However, this dose should be changed appropriately according to future studies and patient conditions, and continuous administration by infusion should be considered.
- the cerebral infarction inhibitor according to the present invention is preferably administered during or after ischemia / reperfusion.
- ischemic reperfusion or after ischemic reperfusion “ischemic reperfusion” and “after ischemic reperfusion” are not clearly distinguished, and for example, ischemic reperfusion such as administration of a thrombolytic agent.
- ischemic reperfusion such as administration of a thrombolytic agent.
- At least pre-ischemic administration is not included in “during or after ischemia-reperfusion”.
- Administration prior to ischemia is practically used as a prophylactic agent. In the case of a cerebral infarction that occurs suddenly and cannot be identified, pre-ischemic administration is not possible.
- administration of histidine prior to ischemia alone does not show an effect in the case of ischemia over a long period of time.
- the cerebral infarction inhibitor of the present invention is administered after reperfusion. This is because it is important to minimize brain tissue necrosis due to reperfusion injury by administration of the cerebral infarction inhibitor of the present invention. More preferably, it is administered immediately after reperfusion.
- the term “immediately” here does not strictly mean immediately after reperfusion, but refers to within 30 minutes after some treatment for ischemia reperfusion such as administration of a thrombolytic agent.
- the cerebral infarction inhibitor of the present invention is preferably administered multiple times or continuously.
- cerebral infarction in many cases of cerebrovascular occlusion, even when blood flow is resumed, restenosis of blood vessels, which are deeply involved in inflammatory cell infiltration by neutrophils, etc., often occurs. Therefore, in the treatment of cerebral infarction, in order to prevent this vascular restenosis and inflammatory reaction, it is necessary to maintain the histamine concentration in the brain tissue for a long time. Specifically, during ischemic reperfusion or immediately after ischemic reperfusion and once every 4-8 hours thereafter, more preferably 2 during ischemic reperfusion or immediately after ischemic reperfusion and every 4-8 hours thereafter. It is preferable to administer more than once (total of 3 or more times). In the case of continuous administration, it is preferable to administer a single dose by infusion or the like over 1 to several hours.
- mice 51 Wistar male rats (body weight: about 300 g), control group (12 animals), 1000 mg / kg histidine administration group (8 animals) before ischemia, post-ischemic 20 Omg / kg histidine administration group (8 animals), 50 Omg / kg histidine administration group after ischemia (10 animals), and 1000 mg / kg histidine administration group (13 animals) after ischemia.
- the rats were anesthetized with a mixture of 2% halothane, 49% oxygen and 49% laughing gas (N 2 o) and allowed to breathe spontaneously. Next, a midline incision was made in the rat's neck on the back, exposing the right common artery.
- the right middle cerebral artery is inserted by inserting silicone-coated 4 ⁇ 0 nylon thread into the right internal artery from the internal carotid and external branches of the common carotid artery. The starting part of was closed. The tip of the nylon thread was placed 18 mm from the branch. After the incision was stitched, the patient recovered from anesthesia. During surgery, an electronic thermometer was inserted into the rectum, and a lamp maintained the rectal temperature at 37.0 ⁇ 0.1 ° C. After recovery from anesthesia, all rats showed paralysis in the contralateral limb.
- Rats were anesthetized again 5 minutes before resuming blood flow. After opening the skin suture, 5 mm of Nylon thread was removed to resume blood flow in the brain 2 hours after middle cerebral artery occlusion. The incision site was sutured again, and physiological saline or histidine (200, 500 or 100 OmgZkg) was intraperitoneally administered. Histidine was once dissolved in a physiological saline adjusted to pH 4.0 with hydrochloric acid, and then returned to pH 6.0 with sodium hydroxide and used. After recovery from anesthesia, food and water were given ad libitum.
- saline or histidine was administered by the abdominal fistula and repeated the same amount as the first administration 6 hours after reperfusion.
- histidine 1 10 minutes before middle cerebral artery occlusion
- anesthesia was performed by intraperitoneal injection of pentobarbital sodium. Thereafter, the brain was perfused with saline containing heparin and decapitated. The brain was quickly removed and rinsed with saline. Crossover and papillary body tail side Between the edges, the brain was sliced in a coronal shape with a thickness of 2 mm, and these brain slices were washed with 37% C 2% triphenyltetrazolium chloride phosphate buffer (0. lmo lZL, pH7. 4). ) Incubated with solution.
- the values in the table indicate the size of the cerebral infarction (mean soil standard deviation), and “*” is significant at 0.05 compared to the control group. This is the case when p was significant at 0.01.
- frozen sections of the control group that perfused the brain 12 and 24 hours later, and each histidine-administered group (4 groups in total) were used as the neutrophil marker Mieguchi.
- Immunostaining was performed with an antibody against bar oxidase. By observing these with an optical microscope, the total number of neutrophils on the ischemic and non-ischemic sides was determined. The results are shown in Table 2.
- frozen slices of a predetermined site obtained from the same rat were immunostained with an antibody against ED1, which is a cell surface marker of macrophages. ED 1 is thought to be present in cells other than macrophages. In fact, ED 1 positive cells were also found on the non-ischemic side in this experiment.
- neutrophil infiltration was observed on the ischemic side at 12 and 24 hours after 2 hours of ischemia.
- neutrophil infiltration after 12 hours was significantly suppressed in the histidine administration group.
- Histidine administration ischemic side 366 soil 149 450 ⁇ 190 363 ⁇ 186
- the cerebral infarction inhibitor of the present invention has few side effects and can effectively suppress cerebral tissue necrosis caused by long-term ischemia due to cerebral thrombosis, cerebral embolism or the like. Therefore, the cerebral infarction inhibitor of the present invention is extremely useful as a cerebral infarction that has been able to reduce cerebral infarction, which has not been particularly effective until now.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/661,700 US20100113544A1 (en) | 2004-09-03 | 2005-09-01 | Suppressant for cerebral infarction attributed to long-time ischemia |
EP05782158A EP1795193B1 (en) | 2004-09-03 | 2005-09-01 | Histidine for suppressing brain tissue necrosis attributed to long-time ischemia |
JP2006532024A JP3987943B2 (ja) | 2004-09-03 | 2005-09-01 | 長時間虚血による脳組織ネクローシスの抑制剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-257612 | 2004-09-03 | ||
JP2004257612 | 2004-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006025598A1 true WO2006025598A1 (ja) | 2006-03-09 |
Family
ID=36000227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016463 WO2006025598A1 (ja) | 2004-09-03 | 2005-09-01 | 長時間虚血による脳梗塞の抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100113544A1 (ja) |
EP (1) | EP1795193B1 (ja) |
JP (1) | JP3987943B2 (ja) |
WO (1) | WO2006025598A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5298028B2 (ja) * | 2007-12-26 | 2013-09-25 | 株式会社大塚製薬工場 | 脳虚血障害治療剤 |
JPWO2016056631A1 (ja) * | 2014-10-08 | 2017-07-27 | 味の素株式会社 | 評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01180823A (ja) * | 1988-01-13 | 1989-07-18 | Sawai Seiyaku Kk | 脳障害処置剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2579596B1 (fr) * | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
US5280038A (en) * | 1992-03-13 | 1994-01-18 | Virginia Commonwealth University | Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome |
US6380254B2 (en) * | 1994-01-24 | 2002-04-30 | Leigh Biotechnology, Inc. | Method and composition for treating and preventing pathogenic effects caused by intracellular calcium overload |
-
2005
- 2005-09-01 JP JP2006532024A patent/JP3987943B2/ja active Active
- 2005-09-01 WO PCT/JP2005/016463 patent/WO2006025598A1/ja active Application Filing
- 2005-09-01 US US11/661,700 patent/US20100113544A1/en not_active Abandoned
- 2005-09-01 EP EP05782158A patent/EP1795193B1/en not_active Not-in-force
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01180823A (ja) * | 1988-01-13 | 1989-07-18 | Sawai Seiyaku Kk | 脳障害処置剤 |
Non-Patent Citations (5)
Title |
---|
ADACHI N. ET AL, BRAIN RESEARCH, vol. 1039, no. 1-2, March 2005 (2005-03-01), pages 220 - 223, XP004798648 * |
ADACHI N. ET AL: "Alleviation of ischemic neuronal damage by postischemic loading with histidine in the rat striatum", BRAIN RESEARCH, vol. 998, no. 1, February 2004 (2004-02-01), pages 136 - 138, XP002998921 * |
DATABASE CAPLUS [online] ADACHI N. ET AL: "Prevention of brain infarction by postischemic administration of histidine in rats", XP003006482, Database accession no. 2005:255930 * |
KAWAMOTO T. ET AL: "Rat Ikkasei Zenno Kyoketsuji ni Okeru L-histidine (singlet oxygen scavenger) no No Hogo Koka", NOSHINKEI, vol. 49, no. 7, 1997, pages 612 - 618, XP002998920 * |
See also references of EP1795193A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5298028B2 (ja) * | 2007-12-26 | 2013-09-25 | 株式会社大塚製薬工場 | 脳虚血障害治療剤 |
JPWO2016056631A1 (ja) * | 2014-10-08 | 2017-07-27 | 味の素株式会社 | 評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006025598A1 (ja) | 2008-05-08 |
EP1795193B1 (en) | 2013-01-09 |
EP1795193A4 (en) | 2009-04-15 |
US20100113544A1 (en) | 2010-05-06 |
EP1795193A1 (en) | 2007-06-13 |
JP3987943B2 (ja) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1014980B1 (en) | Use of tempol for the treatment of essential hypertension | |
US6503947B1 (en) | Method of treating cytotoxic damage | |
JP2010505946A (ja) | 神経再生改善のための補体阻害 | |
WO2000051623A2 (en) | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions | |
KR100720970B1 (ko) | 진세노사이드 Rb₁을 함유하는 뇌세포 또는 신경세포보호제 | |
JP2023153841A (ja) | 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物 | |
KR100696417B1 (ko) | 진세노사이드 Rb₁을 함유하는 뇌혈관 재생ㆍ재구축 촉진제 및 신경조직 이차변성 억제제 | |
CN111093748A (zh) | 含有低浓度氙和氩的气体混合物提供神经保护作用而不抑制血栓溶解剂的催化活性 | |
JP3987943B2 (ja) | 長時間虚血による脳組織ネクローシスの抑制剤 | |
JP3876325B1 (ja) | 脳梗塞抑制剤 | |
WO2013006658A1 (en) | Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide | |
JP5011496B2 (ja) | 脳梗塞抑制剤 | |
JP2004534760A (ja) | 腎線維症の治療 | |
US20060263358A1 (en) | Method for reducing sepsis or cardiogenic shock associated with myocardial injury | |
KR101936836B1 (ko) | 허혈성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
WO2024099346A1 (zh) | 吲唑类化合物在治疗炎症小体激活介导的疾病中的应用 | |
CN110604735B (zh) | 一种治疗肝纤维化、硬皮病的化合物及其应用 | |
RU2343921C2 (ru) | Способ лечения острого инфаркта миокарда | |
KR100540537B1 (ko) | 간경변의 치료방법 | |
US20140100165A1 (en) | Prevention of kidney injury or disease | |
JP2023551455A (ja) | 子癇前症を治療又は予防する薬物の調製におけるザナミビルの使用 | |
CN116482377A (zh) | 靶向trpml1调控自噬对心肌损伤的保护效应 | |
RU2563796C1 (ru) | Способ лечения ишемических нарушений печени | |
CN117100862A (zh) | Mif和ripk1在围术期缺血性脑损伤中的应用 | |
JPH08508710A (ja) | 新規処置方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006532024 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11661700 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005782158 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782158 Country of ref document: EP |